Tavanic

Tavanic is an original brand-name broad-spectrum fluoroquinolone antibiotic containing levofloxacin (manufactured globally by Sanofi). As the pure S-enantiomer of ofloxacin, it exhibits twice the potency of its predecessor by inhibiting bacterial DNA gyrase and topoisomerase IV. This action blocks bacterial DNA replication and repair, leading to rapid bacterial cell death. Tavanic is particularly valued for its excellent tissue penetration and high oral bioavailability.

Primary Medical Indications

Tavanic is indicated for adult patients to treat mild to severe bacterial infections caused by susceptible Gram-positive, Gram-negative, and atypical micro-organisms:

• Lower & Upper Respiratory Tract Infections: Community-acquired pneumonia (CAP), hospital-acquired pneumonia, acute pyelonephritis/sinusitis, and acute exacerbation of chronic bronchitis.

• Urinary Tract & Reproductive Infections: Complicated urinary tract infections (cUTI), acute pyelonephritis, and chronic bacterial prostatitis.

• Skin & Soft Tissue Infections: Complicated and uncomplicated skin and soft tissue infections, including cellulitis, abscesses, and wound infections.

• Special Indications: Post-exposure prophylaxis and treatment of inhalational anthrax and plague.

Key Product Specifications & Dosing Forms

Critical Safety & Clinical Precautions

• FDA / EMA Boxed Warnings: Fluoroquinolones, including Tavanic, carry warnings regarding disabling and potentially irreversible adverse reactions, including tendonitis, tendon rupture (most commonly the Achilles tendon), peripheral neuropathy, and central nervous system effects.

• Chelation Interactions: Absorption is significantly reduced when taken with divalent or trivalent cations. Do not take Tavanic within 2 hours before or 2 hours after antacids containing aluminum or magnesium, iron supplements, sucralfate, or zinc-containing multivitamins.

• Cardiac Safety (QT Interval): Exercise caution in patients with known risk factors for QT prolongation, severe bradycardia, uncorrected electrolyte imbalances, or concurrent use of antiarrhythmic agents.

• Photosensitivity: Patients should avoid unnecessary exposure to strong sunlight and ultraviolet radiation during treatment to prevent cutaneous phototoxicity.